Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib versus docetaxel in HER2 exon 20 mutant NSCLC
NCT04447118Phase 3Completed
- Sponsor
- Hengrui
- Start
- Sep 2020
- Primary completion
- Jun 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 13
01
Overview
A Phase 3 trial of pyrotinib in non-small cell lung cancer (NSCLC), sponsored by Hengrui. Started Sep 2020; status: completed.
02
Drugs
pyrotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04447118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04447118.